The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-oks-subcutaneous-mosunetuzumab-follicular-lymphoma-2025a1001093?src=rss
Author :
Publish date : 2025-12-24 08:06:00
Copyright for syndicated content belongs to the linked Source.
